APLD vs ASML

APLD's deterministic health scores signal severe financial distress: the Piotroski F-Score of 1/9 indicates extreme weakness in operational and financial health, while the absence of an Altman Z-Score raises red flags for potential bankruptcy risk. Despite a remarkable 250% YoY revenue growth and strong earnings surprises in recent quarters, the company operates at a deep loss with a -47.35% profit margin and negative ROE, undermining long-term sustainability. Insider selling totaling $18.85M over six months, including large sales by the CEO and directors, contradicts the 'strong_buy' analyst consensus and suggests internal skepticism. The stock trades at a premium valuation (Price/Sales: 28.65, Price/Book: 5.21) with no intrinsic value or Graham Number available, reflecting speculative pricing rather than fundamental strength.

ASML exhibits strong financial health with a Piotroski F-Score of 4/9, indicating stable fundamentals despite not reaching the 'strong' threshold. The company's robust profitability metrics—especially a 50.46% ROE and 29.42% profit margin—underscore its operational excellence. While the current price of $1,345.69 trades at a premium to both the Graham Number ($193.99) and Intrinsic Value ($507.83), this is justified by exceptional growth prospects and dominant market positioning in semiconductor equipment. The recent earnings beat rate of 50% over the last four quarters and consistent positive surprises support a bullish outlook. The absence of an Altman Z-Score does not indicate distress risk, as the company maintains a low debt-to-equity ratio (0.24) and strong liquidity. Price trades at a 28.2% premium to fair value estimate ($1050.00), limiting near-term upside from a valuation perspective.